Circulating tumor DNA indicates risk of relapse after transplant in DLBCL patients

December 07, 2020

Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists suggests that patients whose blood or stem cell samples harbor tumor DNA are likely to relapse.

The findings, presented today at the virtual 62nd American Society of Hematology (ASH) Annual Meeting, indicate that testing for tumor DNA within a patient's stem cells or blood can be helpful for patients with DLBCL, regardless of whether they're eligible for a transplant or have already undergone one. The results could support studies of alternative treatments, such as CAR T cell therapy, in clinical trials for patients whose stem cells test positive for tumor DNA. Patients who test positive after a transplant may benefit from prompt interventions to guard against relapse.

"Testing for tumor DNA is a powerful technique that can give us information that can be helpful in terms of prognosis and that may be a platform in the future for further personalizing therapies to minimize the risk of relapse for patients with lymphoma," said Dana-Farber's Reid Merryman, MD, the lead author of the study.

DLBCL is the most common type of non-Hodgkin lymphoma in the United States, with more than 18,000 new diagnoses each year. It begins in white blood cells called B cells that, among other roles, make antibodies to fight infections.

Researchers hypothesized that DNA shed from tumor cells into the bloodstream could be an indicator of risk of relapse. To determine if that's the case, they tested for tumor DNA in blood and tissue samples from patients both before and after transplant and compared relapse rates among those who tested positive and those who did not.

The study included 154 patients with DLBCL who had undergone an autologous stem cell transplant (a transplant of their own cells). Researchers analyzed stem cell samples left over from the transplants and blood samples collected after transplant.

They found that patients who had evidence of circulating tumor DNA within their stem cell samples often fared poorly after transplant. Five years after undergoing a transplant, only 13% of them were still in remission, the rest having relapsed.

"This suggests that patients identified prior to transplant as having evidence of circulating tumor DNA should be treated with therapies other than transplant," Merryman stated. "This is an important area to explore as part of a future clinical trial."

Similarly, the presence of tumor DNA in blood samples collected after transplant often indicated a poor prognosis. Of the 20 patients found to have tumor DNA in their blood, 17 went on to relapse. On average, the DNA was detected about two months before the relapse occurred. "This could provide us with some lead time for interventions that may be able to pre-empt relapse from occurring," Merryman remarked. "As in the case of tumor DNA found prior to transplant, the potential value of such interventions needs to be explored in clinical trials."

Merryman will present findings on this study during Session 627, Abstract 531 on Monday, Dec. 7 at 10:15 a.m. EST.
-end-
Complete details on Dana-Farber's activities at ASH are available online at http://www.dana-farber.org/ash.

Dana-Farber Cancer Institute

Related Stem Cells Articles from Brightsurf:

SUTD researchers create heart cells from stem cells using 3D printing
SUTD researchers 3D printed a micro-scaled physical device to demonstrate a new level of control in the directed differentiation of stem cells, enhancing the production of cardiomyocytes.

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

First events in stem cells becoming specialized cells needed for organ development
Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.

Surprising research result: All immature cells can develop into stem cells
New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.

The development of brain stem cells into new nerve cells and why this can lead to cancer
Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.

Healthy blood stem cells have as many DNA mutations as leukemic cells
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

New method grows brain cells from stem cells quickly and efficiently
Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.

NUS researchers confine mature cells to turn them into stem cells
Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.

Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

Read More: Stem Cells News and Stem Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.